safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
Published 2 months ago • 54 plays • Length 3:20Download video MP4
Download video MP3
Similar videos
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:55
phase i/ib safety study of prgn-3006 ultracar-t in patients with r/r cd33-positive aml & hr-mds
-
2:16
cpx-351 in poor risk aml patients
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
2:29
cpx-351 vs 7 3 in older high-risk aml patients
-
3:47
log360 use case: monitoring critical configuration changes
-
2:15
safevisionary2 – safe 3d camera tackles common agv problem and helps avoid collisions
-
19:06
lab safety
-
5:36
venetoclax and azacitidine in mds patients
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
5:42
immune checkpoint inhibitors in mds and aml
-
2:22
session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
1:51
thrombotic and bleeding complications in al amyloidosis
-
0:38
optimal time for allo-hsct in aml
-
1:26
emerging management options for aml